Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979

Publications

Kimura, M., L. L. Bañez, T. J. Polascik, R. M. Bernal, L. Gerber, C. N. Robertson, C. F. Donatucci, and J. W. Moul. “Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction..” Andrology 1, no. 2 (March 2013): 256–61. https://doi.org/10.1111/j.2047-2927.2012.00036.x.

Full Text

Kalman, Noah S., Lionel L. Banez, Leah Gerber, Judd W. Moul, Mitchell Steven Anscher, W Robert Lee, and Bridget F. Koontz. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.56.

Full Text

Moul, Judd W., Hans Lilja, Raymond Lance, Robert Vessella, Jonathan E. McDermed, Mark J. Sarno, and Thomas H. Adams. “Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence..” In Journal of Clinical Oncology, 31:139–139. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.139.

Full Text

Moul, J. W., M. J. Moore, and H. A. Burris. “Oncologist roundtable: Is the Zaltrap pricing reversal a 'watershed moment'?.” In Oncology Report, 2013.

Scholars@Duke

Fu, Q., J. W. Moul, L. Bañez, L. Sun, V. Mouraviev, D. Xie, and T. J. Polascik. “Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance..” Medical Oncology (Northwood, London, England) 30, no. 1 (2013): 326–326.

Scholars@Duke

Fu, Qiang, Judd W. Moul, Lionel L. Bañez, Leon Sun, Vladimir Mouraviev, Dongha Xie, and Thomas J. Polascik. “Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer..” Med Oncol 29, no. 5 (December 2012): 3339–44. https://doi.org/10.1007/s12032-012-0270-4.

Full Text

Stewart, S. B., C. D. Scales, J. W. Moul, and S. D. Reed. “Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?.” Prostate Cancer Prostatic Dis 15, no. 4 (December 2012): 380–85. https://doi.org/10.1038/pcan.2012.26.

Full Text

Moul, Judd W., Hans Lilja, O John Semmes, Raymond S. Lance, Robert L. Vessella, Martin Fleisher, Clarisse Mazzola, et al. “NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy..” Urology 80, no. 6 (December 2012): 1319–25. https://doi.org/10.1016/j.urology.2012.06.080.

Full Text

Pages